PHAR vs. VKTX, KYMR, MOR, CRNX, ALVO, IMVT, CPRX, HCM, OGN, and AMRX
Should you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Viking Therapeutics (VKTX), Kymera Therapeutics (KYMR), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), Immunovant (IMVT), Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), Organon & Co. (OGN), and AMNEAL PHARMACEUTICALS (AMRX). These companies are all part of the "pharmaceutical products" industry.
Pharming Group vs. Its Competitors
Viking Therapeutics (NASDAQ:VKTX) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.
Pharming Group has higher revenue and earnings than Viking Therapeutics. Pharming Group is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.
76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 4.1% of Viking Therapeutics shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Viking Therapeutics currently has a consensus target price of $87.15, indicating a potential upside of 226.79%. Pharming Group has a consensus target price of $30.00, indicating a potential upside of 185.74%. Given Viking Therapeutics' higher probable upside, equities research analysts clearly believe Viking Therapeutics is more favorable than Pharming Group.
In the previous week, Viking Therapeutics had 8 more articles in the media than Pharming Group. MarketBeat recorded 13 mentions for Viking Therapeutics and 5 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.89 beat Viking Therapeutics' score of 0.57 indicating that Pharming Group is being referred to more favorably in the news media.
Viking Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.02, indicating that its share price is 98% less volatile than the S&P 500.
Viking Therapeutics has a net margin of 0.00% compared to Pharming Group's net margin of -4.14%. Pharming Group's return on equity of -6.01% beat Viking Therapeutics' return on equity.
Summary
Viking Therapeutics beats Pharming Group on 9 of the 15 factors compared between the two stocks.
Get Pharming Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pharming Group Competitors List
Related Companies and Tools
This page (NASDAQ:PHAR) was last updated on 7/1/2025 by MarketBeat.com Staff
